Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

24 Oct 2016

Abstract excerpt

BACKGROUND: Although in recent years, the introduction of novel chemotherapy protocols has improved the outcome of T cell acute lymphoblastic leukemia (T-ALL) patients, refractory and/or relapsing disease remains a foremost concern. In this context, a major contribution was provided by the introduction of the nucleoside analog nelarabine, approved for salvage treatment of T-ALL patients with refractory/relapsed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Biochemical and Molecular Research
Share to Cancer therapeutics and mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27776559
DOI: 10.1186/s13045-016-0344-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathwayPMID 27776559Read ↗

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenSemantic proximity Read ↗

Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivationSemantic proximity Read ↗

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemiaSemantic proximity Read ↗

C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4Semantic proximity Read ↗

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.Semantic proximity Read ↗

Zebrafish screen identifies novel compound with selective toxicity against leukemiaSemantic proximity Read ↗

Targeting mTOR in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Proteomic profiling reveals pleiotropic antimetabolite activity of triciribine in acute lymphoblastic leukemiaSemantic proximity Read ↗

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaSemantic proximity Read ↗

Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.